Cargando…

Construction and Evaluation of Clinical Prediction Model for Immunotherapy-related Adverse Events and Clinical Benefit in Cancer Patients Receiving Immune Checkpoint Inhibitors Based on Serum Cytokine Levels

Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of cancer therapy. This study aimed to develop novel risk classifiers to predict the risk of immune-related adverse events (irAEs) and the probability of clinical benefits. Patients with cancer who received ICIs from t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Ni, Jiang, Aimin, Shang, Xiao, Zhao, Fumei, Wang, Ruoxuan, Fu, Xiao, Ruan, Zhiping, Liang, Xuan, Tian, Tao, Yao, Yu, Li, Chunli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Clinical Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473032/ https://www.ncbi.nlm.nih.gov/pubmed/37335173 http://dx.doi.org/10.1097/CJI.0000000000000478

Ejemplares similares

Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Establishment of a risk classifier to predict the in-hospital death risk of nosocomial fungal infections in cancer patients
por: Wang, Ruoxuan, et al.
Publicado: (2023)

Cytokines in clinical cancer immunotherapy
por: Berraondo, Pedro, et al.
Publicado: (2018)

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
por: Husebye, Eystein S, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

Clinical Application of Cytokines in Cancer Immunotherapy
por: Qiu, Yi, et al.
Publicado: (2021)

The Predictive Model Construction for Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immunotherapy
por: Gao, Weitong, et al.
Publicado: (2023)

New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials
por: Jin, Haoer, et al.
Publicado: (2022)

Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy
por: Chikuma, Shunsuke, et al.
Publicado: (2017)

Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer
por: Hu, Yue, et al.
Publicado: (2023)

Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit
por: Cho, Yung-Tsu, et al.
Publicado: (2022)

Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer
por: van Holstein, Yara, et al.
Publicado: (2019)

Precise Therapeutic Benefits and Underlying Mechanisms of Anlotinib Combined With Checkpoint Immunotherapy in Advanced Non-Small-Cell Lung Cancer
por: Xiang, Yi, et al.
Publicado: (2022)

Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma
por: Wang, Qiyu, et al.
Publicado: (2022)

Clinical application and prospect of immune checkpoint inhibitors for CAR-NK cell in tumor immunotherapy
por: Yang, Kangdi, et al.
Publicado: (2023)

Rheumatic Immuno-related Adverse Events following Immunotherapy with Checkpoint Inhibitors: Adverse Drug Reaction, or Other?
por: Manzo, Ciro
Publicado: (2021)

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
por: Bayless, Nicholas L, et al.
Publicado: (2021)

Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials
por: Unger, Joseph M., et al.
Publicado: (2022)

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
por: Jing, Ying, et al.
Publicado: (2022)

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
por: Jing, Ying, et al.
Publicado: (2020)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

Cutaneous and Noncutaneous Adverse Effects in Patients with Advanced Melanoma Receiving Immunotherapy
por: Yeung, Howa, et al.
Publicado: (2023)

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy
por: Zhao, Binghao, et al.
Publicado: (2022)

DNAH7 mutations benefit colorectal cancer patients receiving immune checkpoint inhibitors
por: Yang, Wenjuan, et al.
Publicado: (2022)

Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Zheng, Ying, et al.
Publicado: (2021)

38351 Immune-related adverse events in cancer patients receiving immune checkpoint inhibitors
por: Lucas, Margaret Byrnethew, et al.
Publicado: (2021)

Clinical significance of genetic profiling based on different anatomic sites in patients with mucosal melanoma who received or did not receive immune checkpoint inhibitors
por: Wang, Hai-Yun, et al.
Publicado: (2023)

Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers
por: Ettl, Tobias, et al.
Publicado: (2022)

The Benefits of Receiver Clock Modelling in Satellite Timing
por: Qin, Weijin, et al.
Publicado: (2021)

Emerging phagocytosis checkpoints in cancer immunotherapy
por: Liu, Yu’e, et al.
Publicado: (2023)

A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors
por: Hata, Hiroki, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
por: Chen, Xue, et al.
Publicado: (2022)

Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians
por: Zhou, Huijie, et al.
Publicado: (2023)

Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment
por: Chieng, Jenny Hui Ling, et al.
Publicado: (2022)

Immune checkpoint inhibitors for multiple myeloma immunotherapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors
por: Groeneveld, Geert H, et al.
Publicado: (2020)

Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
por: Biniakewitz, Matthew D., et al.
Publicado: (2020)

Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy
por: Krueger, Janna, et al.
Publicado: (2021)

Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer
por: Hue, Jonathan J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f2cr5drod05s2cfi1fp8ss71in